Caris Life Sciences, Inc. (CAI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Caris Life Sciences went public in June of the previous year, marking a significant milestone as a publicly traded company [2][3] - The company is positioned for transformation in 2025, indicating a strategic focus on growth and development [3] Financial Performance - Caris Life Sciences ended the year with over $800 million in cash, reflecting a 5% increase through the quarter [3] - The company has reported strong performance from a profit and loss perspective, indicating improved financial health post-IPO [3]